

NEW PRODUCT ANNOUNCEMENT

AJOVY™ for the preventive treatment of migraine in adults¹

(fremanezumab)

Teva Pharma New Zealand wishes to advise that AJOVY™ (fremanezumab), a new preventive treatment option for migraine, is now available via private prescription. AJOVY™ is the only anti-CGRP therapy offering the flexibility of quarterly or monthly dosing for migraine prevention.¹⁻⁴



DOSE & ADMINISTRATION

AJOVY™ contains 225 mg fremanezumab in 1.5 mL (150 mg/mL). It is administered by subcutaneous injection using a pre-filled syringe. Two dosing options are available: 225 mg once monthly (monthly dosing) or 675 mg (three injections) every three months (quarterly dosing).¹

STORAGE

AJOVY™ should be stored in a refrigerator (2–8°C). Do not freeze. Keep the pre-filled syringe(s) in the outer carton to protect from light. AJOVY™ may be stored unrefrigerated for up to 7 days at a temperature up to 30°C. It must be discarded if not used within 7 days of removal from refrigeration. AJOVY™ must remain in the outer carton when stored outside the refrigerator.¹

RESOURCES FOR YOUR PATIENTS

Consumer Medicine Information: www.medsafe.govt.nz

Patients can access the 'How to Inject' video and other resources via www.ajovy.co.nz

PLACE AN ORDER

Place your order now to be ready when the first patient comes through the door.

Pharmacode	Brand name	Description	Pack size	Pack UOM	Strength
2718499	AJOVY™	AJOVY™ 225 mg/1.5mL PFS 1	1.0000	inj	225 mg/1.5mL PFS 1

If you would like further information regarding AJOVY™, please contact Teva New Zealand MedInfo on 0800 800 097.

Regards,
Teva Pharma New Zealand Team

CGRP, calcitonin gene-related peptide.

Before prescribing AjoVy™ (fremanezumab), a Prescription Medicine, please review the full Data Sheet for the product available at www.medsafe.govt.nz. AjoVy™ is an unfunded medicine – patients will need to pay for the medicine and any healthcare professional fees.

AjoVy™ (fremanezumab) 225 mg/1.5mL pre-filled syringe. **Indication:** Preventive treatment of migraine in adults. **Contraindications:** Hypersensitivity to the active substance or to any other component of the product. **Precautions:** Hypersensitivity; consider discontinuation and initiate appropriate treatment, Major Cardiovascular Disease; some patient groups with major cardiovascular disease were excluded from clinical trials. No safety data is available in these patients. No data available in elderly or paediatric patients. No data available in renal or hepatic impairment. Pregnancy Category B1; may cross placenta. Lactation, unknown whether fremanezumab is excreted in human milk. No or negligible influence on the ability to drive or operate machinery. **Interactions:** No formal clinical drug interaction studies have been performed. Concomitant Migraine Treatment; concomitant use of acute migraine treatments (analgesics, ergots and triptans) and preventive migraine medications did not influence safety and efficacy. CYP450 Substrates; pharmacokinetic interactions are not expected when co-administered. **Adverse Effects:** The most frequently reported adverse events were local reactions at the injection site [pain (24%), induration (17%), erythema (16%) and pruritus (2%)]. **Very Common:** Injection site pain, injection site induration, injection site erythema. **Common:** Injection site pruritus. **Uncommon:** Hypersensitivity reactions such as rash, pruritus, urticaria and swelling. **Dosage and Administration:** AjoVy™ should only be administered by subcutaneous injection. Treatment should be initiated by a physician experienced in the diagnosis and treatment of migraine. Available in a monthly dose; 225 mg once monthly or a quarterly dose; 675 mg every three months. The treatment benefit should be assessed 8-12 weeks after initiation of treatment. **Missed Dose:** resume dosing on the indicated dose and regimen. Do not administer a double dose. May be administered by healthcare professionals, as well as patients or caregivers upon proper training from their healthcare professional. Syringe is single use in one patient only. Discard any residue. Follow clean injection technique every time. Administer by subcutaneous injection only into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. For multiple injections, do not use the same injection site. **Presentation:** 1.5 mL solution in a 2.25 mL Type I glass syringe with plunger stopper (bromobutyl rubber) and needle. The pre-filled syringe cap is not made with natural rubber latex. Pack sizes of one 225mg/1.5mL or three 225mg/1.5mL pre-filled syringes. Not all pack sizes may be marketed. **Storage:** Store in a refrigerator (2°C to 8°C). Do not freeze. Keep the pre-filled syringe(s) in the outer carton in order to protect from light. May be stored unrefrigerated for up to 7 days at a temperature up to 30°C. Must be discarded if not used within 7 days of removal from refrigeration. **Medical Classification:** Prescription Medicine. Based on Data Sheet v3.0 approved 28 January 2025. **Distributed in NZ by:** Teva Pharma (New Zealand) Limited (No. 1190198) of Tenancy B, Level 14, the AIG Building, 41 Shortland Street, Auckland Central, Auckland 1010 New Zealand. New Zealand Telephone: 0800 800 097

AJOVY™ is a trade mark owned by Teva Pharmaceuticals International GmbH. Date of preparation: December 2025. Date of expiration: December 2027. TEV010. AJO-NZ-00010. TAPS MR12745.

References: 1. AJOVY™ (fremanezumab) Data Sheet 2. EMGALTY (galcanezumab) Data Sheet (00010) (G) Approved Date: 14/12/2025 (ant) Data Sheet.

Document Number: AJO-NZ-00010 Approved Date: 14/12/2025